Akero Therapeutics's total assets for Q3 2024 were $817.55M, a decrease of -5.49% from the previous quarter. AKRO total liabilities were $79.22M for the fiscal quarter, a 18.28% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.